RT Journal Article
T1 A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.
A1 Encinas, Cristina
A1 Hernandez-Rivas, José-Ángel
A1 Oriol, Albert
A1 Rosiñol, Laura
A1 Blanchard, María-Jesús
A1 Bellón, José-María
A1 García-Sanz, Ramón
A1 de la Rubia, Javier
A1 de la Guía, Ana López
A1 Jímenez-Ubieto, Ana
A1 Jarque, Isidro
A1 Iñigo, Belén
A1 Dourdil, Victoria
A1 de Arriba, Felipe
A1 Pérez-Ávila, Clara Cuéllar
A1 Gonzalez, Yolanda
A1 Hernández, Miguel-Teodoro
A1 Bargay, Joan
A1 Granell, Miguel
A1 Rodríguez-Otero, Paula
A1 Silvent, Maialen
A1 Cabrera, Carmen
A1 Rios, Rafael
A1 Alegre, Adrián
A1 Gironella, Mercedes
A1 Gonzalez, Marta-Sonia
A1 Sureda, Anna
A1 Sampol, Antonia
A1 Ocio, Enrique M
A1 Krsnik, Isabel
A1 García, Antonio
A1 García-Mateo, Aránzazu
A1 Soler, Joan-Alfons
A1 Martín, Jesús
A1 Arguiñano, José-María
A1 Mateos, María-Victoria
A1 Bladé, Joan
A1 San-Miguel, Jesús F
A1 Lahuerta, Juan-José
A1 Martínez-López, Joaquín
A1 GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group, 
AB Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 > 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13.8%, and majority of the patients experiencing the first episode before 4 months (11.1%). 1.2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin ≤30 g/L, ECOG > 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0-2) 8.2%; intermediate-risk (score 3) 19.2%; and high-risk (score 4) 28.3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies.
YR 2022
FD 2022-04-19
LK http://hdl.handle.net/10668/19516
UL http://hdl.handle.net/10668/19516
LA en
DS RISalud
RD Apr 6, 2025